Hybrid Oligonucleotides for Selective RNA Stabilization
Solution Overview
Problem
Current methods for modulating gene expression are limited in their ability to selectively increase gene expression levels, particularly in treating diseases associated with decreased gene expression, such as Friedreich's ataxia, where existing approaches fail to effectively target and stabilize specific RNA molecules.
Innovation Solution
Development of hybrid oligonucleotides that combine a cleavage-promoting region and a protective region, allowing for selective cleavage of target RNA while preventing exonuclease degradation, thereby stabilizing and increasing the steady-state levels of the RNA and corresponding protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oligonucleotides are used to block translation or cause degradation of target RNAs, then gene expression is reduced, but the ability to selectively increase gene expression levels is limited
Solution Approach 1:
The oligonucleotide is divided into distinct functional regions: a 5' region (nucleotides 1-10) that promotes endonuclease cleavage of the target RNA, and a 3' region (nucleotides 11-20) that provides steric protection against exonuclease degradation. This segmentation allows the single molecule to simultaneously perform both cleavage and protection functions, enabling selective increase of gene expression levels
Solution Approach 2:
Different regions of the oligonucleotide are assigned different functional properties: the 5' region is designed to promote cleavage activity while the 3' region is designed to provide protective steric blocking. This local differentiation of quality allows the oligonucleotide to achieve both degradation and stabilization effects at different locations along the target RNA molecule
2Manufacturing precision
If target RNA is cleaved to remove undesirable portions, then RNA structure is modified, but the cleaved RNA becomes susceptible to further exonuclease degradation
Solution Approach 1:
The oligonucleotide is designed to perform the protective action at the 3' end before exonucleases can degrade the cleaved RNA. By positioning the protective region to hybridize with the 3' end of the target RNA, the invention preemptively blocks exonuclease access, preserving the cleaved RNA product
Solution Approach 2:
The 3' region of the oligonucleotide acts as an intermediary that physically blocks the interaction between exonucleases and the cleaved RNA. This steric blocking region serves as a mediator that prevents the harmful degradation action without interfering with the desired cleavage function
3Reliability
If existing approaches are used to treat diseases with decreased gene expression, then treatment options are limited, but effective targeting and stabilization of specific RNA molecules is not achieved
Solution Approach 1:
The invention merges two previously separate functions (cleavage promotion and exonuclease protection) into a single oligonucleotide molecule. This combination approach simplifies the therapeutic strategy by using one agent instead of multiple components, making the approach more feasible for clinical application while achieving effective targeted RNA stabilization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hybrid oligonucleotides effectively increase gene expression levels by stabilizing target RNA and promoting the production of specific proteins, demonstrating potential in treating conditions like Friedreich's ataxia by selectively targeting and modifying gene expression.
Implementation Method 1
promotes cleavage (e.g., via endonuclease activity) of a target nucleic acid
Implementation Method 2
protects the nucleic acid from cleavage (e.g., via exonuclease activity) at another position
Data Source
AI summary
Provided herein are hybrid oligonucleotides comprising a region that promotes cleavage of a nucleic acid and a region that protects a nucleic acid from exonuclease activity. Such hybrid oligonucleotides are useful for modulating the expression of genes. Related compositions and methods are also provided. In some embodiments, methods are provided for treating a disease, such as by administering a hybrid oligonucleotide.



